MoonLake Immunotherapeutics Stock Plummets After Phase 3 Data Readouts
MoonLake Immunotherapeutics‘ (NASDAQ: MLTX) stock price fell off a cliff Monday after it reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials.
Benzinga ·
Benzinga
